{"id":"W2135497148","doi":"10.1158/1538-7445.am2013-lb-289","title":"Abstract LB-289: A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors.","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"Arbutus Biopharma (Canada)","funders":"","keywords":"Medicine; PLK1; Pharmacokinetics; Chills; Adverse effect; Pharmacodynamics; Kinase; Pharmacology; Neutropenia; Cmax; Nausea; Cell cycle; Internal medicine; Toxicity; Oncology; Cancer research; Cancer; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001312503,0.001179683,0.001623199,0.000369484,0.0004093403,0.0008785119,0.0009924443,0.0008251896,0.002605534],"category_scores_gemma":[0.0006531249,0.0004576796,0.001010742,0.0003680624,0.0008234889,0.0005150877,0.0003709414,0.003625056,0.0009106563],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001154347,"about_ca_system_score_gemma":0.001692666,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001450486,"about_ca_topic_score_gemma":0.002919152,"domain_scores_codex":[0.9996368,0.0001544086,0.00002459905,0.00006125277,0.00005418938,0.00006878952],"domain_scores_gemma":[0.999441,0.00009443673,0.0000988879,0.00005483214,0.00004418801,0.0002666462],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3645823,0.1698309,0.02027585,0.001140004,0.001580783,0.0006960417,0.0005478748,0.005043109,0.2527675,0.0004699765,0.008149543,0.1749161],"study_design_scores_gemma":[0.2959076,0.6498952,0.02524658,0.00004123868,0.0005468758,0.0006509282,0.0001054708,0.003208481,0.02046941,0.0001746632,0.00371442,0.0000391853],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940642,0.0011999,0.0008381463,0.000294391,0.00006548492,0.001487403,0.000714162,0.0001300794,0.00120639],"genre_scores_gemma":[0.991001,0.0007538471,0.002309919,0.0005278958,0.00006445699,0.001591578,0.001995304,0.00003613242,0.001719803],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002605534,"threshold_uncertainty_score":0.008716345,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02498979643351203,"score_gpt":0.3614604390467197,"score_spread":0.3364706426132076,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}